AMARIN ANNOUNCES PRECLINICAL RESULTS OF MIRAXION STUDY

A A

Amarin has reported data from two preclinical studies of Miraxion (ultra pure ethyl-EPA).

The studies demonstrated that Miraxion improved learning and memory, had multiple neuroprotective effects and improved cell viability thereby slowing neuronal apoptosis (cell death) which is often associated with a number of neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases. Miraxion is currently undergoing two Phase III clinical trials in Huntington's disease under a special protocol assessment agreed with the FDA, and has been granted fast-track designation by the agency. Miraxion is also in Phase II development for depressive disorders and preclinical development for Parkinson's disease.